Hyperthermic intraperitoneal chemotherapy

Last revised by Thomas Lausen on 16 Oct 2023

Citation, DOI, disclosures and article data

Citation:

Weerakkody Y, Lausen T, Bell D, et al. Hyperthermic intraperitoneal chemotherapy. Reference article, Radiopaedia.org (Accessed on 11 May 2024) https://doi.org/10.53347/rID-83274

DOI:

https://doi.org/10.53347/rID-83274

Permalink:

https://radiopaedia.org/articles/83274

rID:

83274

Article created:

18 Oct 2020, Yuranga Weerakkody ◉

Disclosures:

At the time the article was created Yuranga Weerakkody had no recorded disclosures.

View Yuranga Weerakkody's current disclosures

Last revised:

16 Oct 2023, Thomas Lausen

Disclosures:

At the time the article was last revised Thomas Lausen had no financial relationships to ineligible companies to disclose.

View Thomas Lausen's current disclosures

Revisions:

4 times, by 4 contributors - see full revision history and disclosures

Systems:

Gastrointestinal, Oncology

Synonyms:

Intraperitoneal hyperthermic chemoperfusion

Hyperthermic intraperitoneal chemotherapy (often abbreviated as HIPEC) is a form of chemotherapy used for the treatment of peritoneal involvement with malignancy.

It usually involves the instillation of heated (to around 41–43°C) chemotherapy agents directly into the abdominopelvic cavity immediately after surgery. It delivers a high dose directly to the site of potential residual microscopic cancer cells while minimizing systemic toxicity. Heating to this temperature is thought to increase drug penetration and cytotoxicity.

The patient can be gently rocked during the procedure to ensure maximum dispersion of the chemotherapy throughout the cavity. It is typically instilled for around 60–90 minutes and then drained.